Cytokine-induced killer cells interact with tumor lysate-pulsed dendritic cells via CCR5 signaling.

[1]  Q. Qian,et al.  The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors , 2015, Experimental Hematology & Oncology.

[2]  Yan-chun Li,et al.  Bioactivity of umbilical cord blood dendritic cells and anti-leukemia effect. , 2015, International journal of clinical and experimental medicine.

[3]  C. Ji,et al.  Immunomodulatory effect of DC/CIK combined with chemotherapy in multiple myeloma and the clinical efficacy. , 2015, International journal of clinical and experimental pathology.

[4]  Liping Wang,et al.  Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. , 2015, Cancer letters.

[5]  J. Hong,et al.  Platycodon grandiflorum polysaccharide induces dendritic cell maturation via TLR4 signaling. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[6]  J. Gutkind,et al.  Melanoma cell lysate induces CCR7 expression and in vivo migration to draining lymph nodes of therapeutic human dendritic cells , 2014, Immunology.

[7]  Jian-ying Zhang,et al.  Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  C. Contag,et al.  A killer choice for cancer immunotherapy , 2014, Immunologic Research.

[9]  Y. Zou,et al.  Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells , 2014, British Journal of Cancer.

[10]  P. Kunda,et al.  Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells. , 2013, Oncology reports.

[11]  Y. Yun,et al.  Decreased pain responses of C–C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli , 2013, Neuropharmacology.

[12]  J. Hong,et al.  Activation of macrophages by polysaccharide isolated from Paecilomyces cicadae through toll-like receptor 4. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  J. Hong,et al.  Adjuvant effect of a natural TLR4 ligand on dendritic cell-based cancer immunotherapy. , 2011, Cancer Letters.

[14]  S. Beissert,et al.  Structure and duration of contact between dendritic cells and T cells are controlled by T cell activation state , 2006, European journal of immunology.

[15]  C. Moratz,et al.  Rgs1 and Gnai2 regulate the entrance of B lymphocytes into lymph nodes and B cell motility within lymph node follicles. , 2005, Immunity.

[16]  S. Zhang,et al.  Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates. , 2004, Leukemia research.

[17]  Robert S Negrin,et al.  Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. , 2004, Blood.

[18]  S. Henrickson,et al.  T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases , 2004, Nature.

[19]  R. Negrin,et al.  Studies of ex Vivo Activated and Expanded CD8+ NK-T Cells in Humans and Mice , 2002, Journal of Clinical Immunology.

[20]  T. Sauerbruch,et al.  Interactions Between Dendritic Cells and Cytokine-Induced Killer Cells Lead to an Activation of Both Populations , 2001, Journal of immunotherapy.

[21]  I. Weissman,et al.  Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity , 1991, The Journal of experimental medicine.

[22]  Jin Gao,et al.  Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy. , 2016, Cytotherapy.

[23]  C. Klein,et al.  Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. , 2011, Blood.